0723 GMT - A late-stage trial showed that Roche's advanced breast cancer drug Itovebi not only delays disease progression but that these patients also live longer, Vontobel analyst Stefan Schneider says in a note. "Itovebi was already approved for first-line therapy on its primary endpoint last October and today's secondary endpoint reinforces that today," the analyst says. Vontobel leaves unchanged its 1.5 billion Swiss francs peak sales estimate for the drug in 2025.(helena.smolak@wsj.com)
(END) Dow Jones Newswires
January 28, 2025 02:24 ET (07:24 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.